Cooper Companies stock gains after activist JANA pushes for CEO change

Published on 09/19/2026 at 11:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cooper Companies stock rebounded on September 18, 2026 after activist investor JANA Partners urged the board to launch an external CEO search and consider asset sales. The move follows weak Q3 2026 revenue of USD 1.07 billion and lowered fiscal 2026 guidance.

COO, US2166481027, Illustration mit AI erstellt.

Cooper Companies stock (ISIN US2166481027) recovered part of its recent losses on September 18, 2026 after activist investor JANA Partners publicly urged the board to initiate an external search for a new CEO and evaluate asset sales to unlock value for shareholders.

Activist letter follows guidance cut

As WowkTV reported on September 18, 2026, JANA Partners sent a detailed letter dated September 17, 2026 to The Cooper Companies board calling for an external CEO search, a new board chair and the evaluation of asset sales after what it describes as chronic underperformance and missteps in strategy.

According to Reuters on September 18, 2026, Cooper had recently lowered its annual forecasts and ended a strategic review of its CooperSurgical unit without pursuing a sale, which JANA argues has hurt investor confidence and weighed on the medical device maker's valuation.

The activist pressure comes shortly after Cooper Companies reported its third quarter of fiscal 2026 results, where revenue fell short of expectations and guidance was cut, triggering a sharp selloff in the stock.

Q3 2026 results show revenue miss and destocking impact

Cooper Companies reported fiscal Q3 2026 revenue of approximately USD 1.07 billion, below consensus estimates of roughly USD 1.10 billion, which contributed to a 14.7 percent drop in the share price following the release on September 9, 2026, according to Finance Yahoo.

Within that total, CooperVision segment revenue in Q3 2026 came in at USD 717 million, described as virtually unchanged year-over-year as U.S. channel destocking masked mid-single-digit consumption growth, according to GuruFocus.

The destocking decision weighed on performance and prompted a reduction in guidance for the remainder of fiscal 2026, with the company citing proactive reductions in U.S. channel inventory in CooperVision as a key factor, according to KXAN on September 18, 2026.

Despite the revenue miss, Cooper Companies delivered adjusted earnings per share of USD 1.15 in Q3 2026, topping Wall Street's consensus of USD 1.12, which shows that margins and cost control were more resilient than top-line growth, as highlighted by KXAN.

Guidance cut and Q4 2026 outlook weigh on sentiment

Cooper Companies lowered its fiscal 2026 adjusted EPS forecast to a range of USD 4.51 to USD 4.55, down from prior expectations and below analysts' estimates, according to Finance Yahoo.

At the same time, the company reduced its fiscal 2026 revenue outlook to between USD 4.23 billion and USD 4.25 billion, which is lower than previous guidance and analysts' prior expectations, reinforcing concerns about the pace of growth in its core businesses, as described by Finance Yahoo.

Looking ahead to Q4 2026, Cooper Companies has guided for non-GAAP EPS between USD 1.05 and USD 1.09 and revenue in the range of USD 1.057 billion to USD 1.080 billion, according to GuruFocus.

Within this outlook, CooperVision's organic sales are forecast to decline by about 2 percent or remain flat in Q4 2026, highlighting ongoing pressure from the inventory reduction and softer demand trends, according to GuruFocus.

Segment trends and strategic review outcome

In Q3 2026, CooperSurgical achieved about 3 percent organic growth, supported by roughly 5 percent growth in fertility services, according to GuruFocus.

Despite buyer interest in assets within CooperSurgical, Cooper Companies concluded a strategic review without pursuing a sale, a decision that JANA now criticizes as a missed opportunity to unlock value and simplify the portfolio, according to Reuters.

JANA's letter argues that Cooper's assets, including fertility and medical device businesses under CooperSurgical, could command a valuation premium under different ownership and that the current conglomerate structure contributes to a discount in the public market, as outlined by WowkTV.

Stock reaction and valuation backdrop

Following the Q3 2026 earnings release and guidance cut on September 9, 2026, Cooper Companies shares fell about 14.7 percent, reflecting investor concern over weaker-than-expected revenue and reduced outlook, according to Finance Yahoo.

Since August 31, 2026, Cooper Companies shares have declined approximately 23 percent, underscoring the magnitude of the valuation compression that has taken place as investors digested weak guidance and operational challenges, according to GuruFocus.

However, Cooper Companies stock moved higher after JANA's letter became public, with shares up about 3.02 percent at USD 55.40 at the time of publication on September 18, 2026, according to NewsBreak/Benzinga.

In pre-market trading on the same day, shares were reported at USD 54.10, 0.60 percent above the prior close, after having ended the previous regular session 1.53 percent lower, according to RTTNews.

Risks and what matters for investors

For investors, the central risk highlighted across recent commentary is the potential for continued revenue pressure if U.S. channel destocking persists longer than expected and if CooperVision fails to translate underlying consumption growth into reported sales, as emphasized by GuruFocus.

Additionally, the lowered fiscal 2026 EPS and revenue guidance suggests that profitability and growth may remain under pressure through at least the next quarter as the company works through inventory adjustments and executes its revised capital allocation and operational plans, as outlined by Finance Yahoo.

Against this backdrop, JANA's calls for leadership change and asset sales could act as a potential catalyst for strategic shifts that might alter Cooper Companies' risk profile and valuation over time, though the eventual impact will depend on how the board responds and what specific actions are taken.

Cooper Companies stock price and trading context

Cooper Companies stock is listed on Nasdaq in USD; recent trading around mid-September 2026 has seen the shares move in the mid-USD 50 range following both the Q3 2026 selloff and the subsequent rebound linked to JANA's activist campaign.